NJ-OPEX
11.3.2024 15:01:27 CET | Business Wire | Press release
OPEX® Corporation, a global leader in Next Generation Automation for almost 50 years, today announced the launch of its newest automated sorting and order retrieval solutions―OPEX Sure Sort® X with OPEX Xtract™. These innovative technologies were officially unveiled by company leadership at MODEX 2024, the largest manufacturing and supply chain trade event, held this year at the Georgia World Congress Center in Atlanta.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240311187962/en/
OPEX® Sure Sort® X with OPEX Xtract™ (Photo: Business Wire)
OPEX Sure Sort X represents the next generation of high-speed, automated sorting. It is the most robust industrial sorting solution available in the market, unmatched in terms of its compact footprint, performance rates, and cost-effectiveness. This universal system can handle nearly 100% of customer-sortable items weighing up to 20 pounds (9 kg), and sort items into a configurable array of mixed bin sizes and types.
When Sure Sort X is paired with Xtract―OPEX’s revolutionary new automated order retrieval system―the task of retrieving totes and transferring their contents into shipping containers is now fully automated, as well. The result is a one-touch solution that can eliminate the need to manually sort and transfer boxes downstream.
"OPEX remains dedicated to innovations that align with the evolving demands of the market," stated Alex Stevens, President of Warehouse Automation at OPEX. "We have received feedback from our customers that they want one integrated solution to sort, retrieve, and automatically get the product into its final container. Our new solutions, Sure Sort X and Xtract, are a response to those requests. This cutting-edge technology is designed to automate multiple manual tasks with a simple, one-touch solution.”
Developed based on feedback from the international business community, Sure Sort X applies OPEX Corporation’s innovative, industry-leading Sure Sort technology, introduced in 2017. With its enhanced product handling capabilities, Sure Sort X is the single most versatile and configurable sorting solution available. It can handle items 60 percent smaller, nearly 20 percent larger, and up to 300 percent heavier than its predecessor, all while maintaining a consistent throughput of up to 2,100 items per hour.
The system’s iBOT® delivery vehicles utilize sophisticated motion algorithms that allow them to maneuver throughout the system efficiently, with the ability to change destination in real time while in transit. These iBOTs can drive in and out of the system while Sure Sort X continues to run, ensuring the highest level of uptime and availability. In addition, Sure Sort X can operate in both chilled and ambient environments. Installation can occur in as little as one week.
OPEX Xtract can be added to any Sure Sort X system by introducing retrieval iBOTs to work in conjunction with the traditional sortation iBOTs found in Sure Sort X. Xtract iBOTs move in a loop that has both horizontal and vertical segments within the Sure Sort X aisle, and can handle up to 200 extracted totes per hour. All of the iBOTs are self-charging and can easily be added to or removed from the system.
The system can retrieve standard totes or can be outfitted with Xtract totes, which are uniquely designed to transport items from the sort location to any available roller, v-chute, transfer (RVT) module. If these totes are used, once all products for a relevant order have been deposited into the Xtract totes, each tote is retrieved and transported to the RVT module, where the tote door opens and releases the items into the final shipping box or order container.
Soon after its unveiling in the US at MODEX, Sure Sort X will make its European debut at the LogiMAT expo in Stuttgart, Germany, on March 19, 2024, at the OPEX exhibit in Hall 7, Stand 7D53.
Sure Sort X and Xtract join the existing Warehouse Automation portfolio at OPEX, which includes Sure Sort®—the industry-leading, high-speed, small-item robotic sorting system; Perfect Pick®, a robotic goods-to-person picking solution that dramatically improves speed, efficiency, and reliability, and Infinity®―the most advanced goods-to-person solution available in warehouse automation. All are custom configured for each client and designed to completely transform supply chain infrastructure.
For nearly five decades, OPEX Corporation has served as a trusted partner, collaborating closely with clients to develop customized, scalable solutions that transform how business is conducted. OPEX continuously reimagines automation technology to help clients solve their most significant business challenges, today and in the future.
About OPEX
OPEX® Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ, USA—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has more than 1,600 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and in the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311187962/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom